AMGN

The company was founded in 1980 in Thousand Oaks as Applied Molecular Genetics, a name later compressed to Amgen. It began with a small group of scientists, venture capital backing, and a thesis that recombinant DNA could be used to manufacture human proteins as medicines. That thesis took years to pay off. The breakthrough came with two products. Epogen, a synthetic version of the hormone erythropoietin that stimulates red blood cell production, won approval in 1989 and gave the company a large revenue base from dialysis patients. Neupogen, which boosts white blood cell counts in chemotherapy patients, followed in 1991. These two drugs funded everything that came after. They established Amgen as the first biotechnology company to convert laboratory science into blockbuster commercial products, and they set the template the company has followed ever since, which is to find a protein that the body uses to regulate a biological process, manufacture it or block it, and sell it into a large patient population.

What Amgen sells today is a diversified set of biologic medicines organized loosely around several therapeutic areas. In cardiovascular disease the lead product is Repatha, an injectable antibody that lowers LDL cholesterol in patients who cannot reach their targets on statins alone. In bone health the company sells Prolia for osteoporosis and Evenity for postmenopausal women at high fracture risk, both built on the same underlying biology of bone remodeling. In inflammation it sells Tezspire, an asthma antibody developed with AstraZeneca, and Otezla, an oral psoriasis drug acquired from Celgene in 2019 for roughly 13 billion dollars. In oncology it sells Blincyto and Kyprolis for blood cancers, Lumakras for certain lung tumors, and newer launches in small cell lung cancer. The rare disease franchise, the most recent major addition, came through the Horizon acquisition and includes Tepezza for thyroid eye disease, Krystexxa for chronic gout, and Uplizna for a rare neurological disorder. Layered across all of this is a growing biosimilars business, in which Amgen manufactures lower cost copies of biologic drugs whose patents have expired, including versions of products originally sold by competitors.

The economic engine has historically rested on three advantages. The first is the difficulty of making biologic drugs at all. Unlike chemical pills, which competitors can copy precisely once a patent lapses, biologics are large proteins grown in living cells, and reproducing them requires enormous manufacturing investment and regulatory scrutiny. That complexity slows the arrival of competition and lets successful biologics hold pricing power for years. The second advantage is scale in manufacturing. Amgen has spent decades and billions of dollars building bioreactor capacity and has invested in newer techniques that lower the cost and footprint of production, which gives it a structural cost position that few rivals can match and which also underpins its biosimilars push. The third advantage is the installed base of physicians and payers built around its established franchises, which gives each new product a commercial channel that is already in place. The combination has produced strong and durable cash flow, which the company has returned to shareholders through dividends and buybacks while also funding research and acquisitions.

The acquisition habit is central to understanding Amgen. The company has repeatedly used its balance sheet to buy revenue and pipeline rather than rely solely on internal discovery. The Otezla purchase in 2019 added a fast growing oral inflammation drug. The 2023 acquisition of Horizon Therapeutics, completed for roughly 28 billion dollars after a regulatory challenge from the Federal Trade Commission, was far larger and reshaped the company. It brought a portfolio of rare disease medicines aimed at small patient populations with severe conditions, products that command high prices and face limited competition. The strategic logic was to offset the slow erosion of older drugs facing patent expiry by buying newer franchises with longer runway. The deal was financed substantially with debt, which raised the company's leverage and made the performance of the acquired drugs, particularly Tepezza, an important variable in the years that followed.

The defining strategic bet of the current era is obesity. The market for weight loss drugs has expanded rapidly on the back of the GLP-1 class, dominated commercially by Novo Nordisk and Eli Lilly, and Amgen is attempting to enter it with a differentiated candidate. MariTide is a monthly injectable designed to require less frequent dosing than the weekly injections that lead the market today, and it works through a dual mechanism that activates one gut hormone receptor while blocking another. In a Phase 2 study reported in 2025, the drug produced meaningful weight loss in patients with obesity, and Amgen moved it into a broad Phase 3 program spanning chronic weight management, cardiovascular outcomes, heart failure, and obstructive sleep apnea. The commercial stakes are large. If MariTide succeeds and the monthly schedule proves to be a genuine advantage in convenience and adherence, it could become a major franchise in one of the fastest growing categories in medicine. If it disappoints on efficacy, tolerability, or differentiation, the investment and the expectations built into the company will have to be reset.

Competition runs across every part of the business and takes several forms. In its established therapeutic areas Amgen competes with the large pharmaceutical companies and with other biotechnology firms developing rival mechanisms. In obesity it faces two entrenched leaders in Novo Nordisk and Eli Lilly, both of which have years of commercial momentum, manufacturing scale, and pipelines of their own, along with a crowded field of other entrants. In biosimilars it competes against other manufacturers pursuing the same expired biologics, a business where margins compress as more copies enter. And across its older franchises it faces the most predictable competitor of all, which is the expiration of its own patents and the biosimilar copies of its own drugs that follow.

Leadership has been notably stable. Robert Bradway has served as Chief Executive Officer since 2012 and is also Chairman of the Board, making him one of the longest serving chief executives in the industry. He joined Amgen in 2006 from an investment banking background and rose through the finance and operating ranks before taking the top job, and his tenure has been defined by capital discipline, a willingness to use large acquisitions to renew the portfolio, and the high stakes push into obesity and cardiometabolic disease. The board pairs his combined chairman and chief executive role with a separate lead independent director. The culture remains rooted in the company's origins as a science driven manufacturer, with deep institutional expertise in protein engineering and large scale biologic production.

The risks are specific and material. The most structural is the patent cliff. Biologic drugs lose exclusivity over time, and several of Amgen's important products are at or approaching that point. The patents protecting Prolia and Xgeva, two of its bone health products, expired in the United States in early 2025, and biosimilar competition for them began the same year, which will erode a meaningful revenue stream. Enbrel, once one of the company's largest products, has been in long decline under biosimilar and pricing pressure. The company's answer to this erosion is the pipeline and the acquired franchises, which means execution risk is concentrated in a handful of bets. MariTide carries the binary risk inherent in any large clinical program, where a single disappointing trial readout can change the company's trajectory. The Horizon acquisition added a second concentration, since the debt taken on to finance it raised leverage and the return on that capital depends heavily on how the rare disease drugs, especially Tepezza, perform against their own competitive and reimbursement pressures. Drug pricing policy in the United States, including the provisions of recent legislation that allow government negotiation of certain drug prices, adds a regulatory overhang that affects the whole industry and Amgen with it.

The forward question for Amgen is whether its two engines of renewal, internal pipeline and large acquisitions, can outrun the steady erosion of its established franchises. The company has done this before. It has survived multiple patent cliffs by manufacturing biosimilars of others' drugs, by buying revenue when its own began to mature, and by reinvesting cash flow into the next generation of products. The current cycle raises the stakes because the largest single bet, obesity, sits in a category already dominated by two formidable competitors, and because the Horizon deal added leverage that makes the margin for error thinner than it once was. An investor weighing Amgen is therefore weighing a proven operator with a durable manufacturing moat and a long record of capital allocation against a portfolio in transition, where the durability of tomorrow's revenue depends on clinical outcomes and competitive battles that have not yet been decided. The live price and fundamentals shown above this profile capture how the market is currently scoring that balance.